In vitro activities of SCH27899 alone and in combination with 17 other antimicrobial agents

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2996-2997

  Fuchs, Peter C ^a   Barry, Arthur L ^a   Brown, Steven D ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; EVERNIMICIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; IMIPENEM; RIFAMPICIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032762934     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2996     Document Type: Article

References (10)

1. Adrian, P. V., and K. P. Klugman. 1998. Ribosomal protein L16: the putative target site for everninomicin (SCH27899) action in Streptococcus pneumoniae, abstr. C-110. In Abstracts of the 38th ICAAC.
2. Black, T. A., W. Zhao, K. J. Shaw, and R. S. Hare. 1998. Physiological investigation on the mechanism of action of SCH27899 (Ziracin), abstr. C-106. In Abstracts of the 38th ICAAC.
3. Cormican, M. G., and R. N. Jones. 1996. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and non-pneumococcal streptococci. Drugs 51(Suppl. 1):6-12.
4. Jones, R. N., and M. S. Barrett. 1995. Antimicrobial activity of SCH27899, oligosaccharide member of the everninomicin class with a wide Gram-positive spectrum. Clin. Microbiol. Infect. 1:35-39.
5. Murakami, H., H. Hanaki, K. Sasaki, Y. Inaba, N. Hori, and K. Hiramatsu. 1998. In vitro activity of everninomicin (EVNM, Ziracin), a new injectable antibiotic, against clinically isolated strains including vancomycin low-resistant Staphylococcus aureus and VRE, abstr. E-120. In Abstracts of the 38th ICAAC.
6. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Tsitsi, J. M. L., A. D. Calver, B. Luke, J.-J. Garaud, P. Grint, J. Gupte, and J. C. Wherry. 1998. A double-blind, randomized, multicenter study of Zircin™ versus ceftriaxone in patients with S. pneumoniae pneumonia, abstr. L-109. In Abstracts of the 38th ICAAC.
8. Uematsu, T., O. Kozawa, S. Nagashima, M. Kanamaru, and Y. Ochi. 1998. Single-dose safety, tolerance, and pharmacokinetics of SCH27899 (Ziracin) in healthy male Japanese volunteers, abstr. A-48. In Abstracts of the 38th ICAAC.
9. Urban, C., N. Mariano, K. Mosinka-Snipas, C. Wadee, T. Chahrour, and J. J. Rahal. 1996. Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin. J. Antimicrob. Chemother. 37:361-364.
10. Weinstein, M. J., G. M. Luedemann, E. M. Oden, and G. H. Wagman. 1965. Everninomicin, a new antibiotic complex from Micromonospora carbonacea, p. 24-32. Antimicrob. Agents Chemother. 1964.